Butyrylcholinesterase and progression of cognitive deficits in dementia with Lewy bodies.
Butyrylcholinesterase is implicated in the pathology of AD. Selective inhibitors increase acetylcholine and improve cognitive function in animal models. In dementia with Lewy bodies, cholinergic activities are more affected than in AD. The authors report a highly significant association between temporal cortex butyrylcholinesterase activity and the rate of cognitive decline in a prospectively studied, autopsy-confirmed dementia with Lewy bodies series.
Perry
Elaine
E
Institute for Ageing and Health, Wolfson Research Centre, Newcastle General Hospital, Newcastle, UK. e.k.perry@ncl.ac.uk
McKeith
Ian
I
Ballard
Clive
C
D000368:Aged; D002091:Butyrylcholinesterase / Q000378:metabolism*; D003072:Cognition Disorders / Q000175:diagnosis* / Q000201:enzymology; D018450:Disease Progression; D005260:Female; D006801:Humans; D020961:Lewy Body Disease / Q000175:diagnosis* / Q000201:enzymology; D008297:Male; D011446:Prospective Studies; D013702:Temporal Lobe / Q000201:enzymology
D002091:Butyrylcholinesterase